Navigation Links
LA BioMed researcher honored for research paper

LOS ANGELES (Sept. 3, 2014) The North American Menopause Society (NAMS) will present Los Angeles Biomedical Research Institute (LA BioMed) researcher Rowan T. Chlebowski, MD, PhD, with the 2014 NAMS Lippincott/Williams & Wilkins Menopause Journal Best Paper Award at its annual meeting in Washington, D.C. in October.

The organization, which is dedicated to promoting the health and quality of life of all women during midlife and beyond, will recognize Dr. Chlebowski for his article, "Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial."

This article was selected from all articles published in 2013, and the presentation of the award will take place at the NAMS 2014 Annual Meeting Oct. 15-18.

"Congratulations to Dr. Chlebowski for this honor for his scholarship and research," said David I. Meyer, PhD, LA BioMed president and CEO. "Dr. Chlebowski is a leader in both cancer prevention and women's health. The article, which won the award, is one of several significant studies he has authored or co-authored from the Women's Health Initiative, one of the largest U.S. prevention studies of its kind."

In addition to his research at LA BioMed, Dr. Chlebowski is the chief of Medical Oncology and Hematology at the Harbor-UCLA Medical Center and a professor of medicine at the UCLA David Geffen School of Medicine. He earned his doctorate degree in reproductive biology at Case Western Reserve University, where he also earned his medical degree.

After an internship and residency in internal medicine at Cleveland Metropolitan General Hospital, Dr. Chlebowski's fellowship brought him to the University of Southern California's School of Medicine. He has held positions in the UCLA health system since 1979.

Recently, Dr. Chlebowski has been best known for his work on significant clinical trials related to breast cancer prevention and therapy and women's health. He reported results of the Women's Intervention Nutrition Study, a multicenter adjuvant trial where a lifestyle intervention reduced breast cancer recurrence, at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.

As a Women's Health Initiative investigator, Dr. Chlebowski led reports on estrogen alone and estrogen plus progestin influence on cancer endpoints. The findings have substantially changed clinical use of menopausal hormone therapy worldwide with an associated reduction in breast cancer incidence. He was also the recipient of the 2012 ASCO/American Cancer Society Award.


Contact: Laura Mecoy
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

Related medicine news :

1. Drexel College of Medicine’s Graduate School of Biomedical Sciences & Professional Studies to Host Conference to Help Graduate Students Find Careers Beyond the Bench
2. University of Nevada, Reno continues $10 million biomedical studies for COBRE grant
3. UMMS scientist named 2014 Pew Latin American Fellow in the biomedical sciences
4. Endocrine Society honors Sen. Dick Durbin with Biomedical Research Champion Award
5. Tufts University licenses silk biomaterials technology to Akeso Biomedical
6. LA BioMed researchers report on promising new therapy for devastating genetic disorder
7. Pitts Center for Medical Innovation announces pilot funding for biomedical technology
8. New biomedical diagnostics using personalized 3-D imaging
9. NCCS and Clearbridge Biomedics open the regions first circulating tumor cell center
10. LA BioMed study finds daily antibiotics most effective in preventing recurrent urinary tract infection
11. A New Player In Biomedical Equipment Opens Headquarters in San Diego
Post Your Comments:
Related Image:
LA BioMed researcher honored for research paper
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Beddit® has launched ... Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that rates ... how well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... -- --> --> ... das Patent über eine neue Hepatitis-B-Behandlung, welches sie gemeinsam ... Enyo Pharma vergeben haben. Im Rahmen ... von Edelris gemeinsam mit seinen Partnern Inserm und Poxel ... identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die zu ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology: